Paris – 25 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs , today announced the listing of Theraclion, an echotherapy specialist using high-intensity focused ultrasound (HIFU) for non-invasive treatment of tumours, on Alternext in Paris.
Founded in 2004, Theraclion is a French company that offers a totally non-invasive treatment for benign breast and thyroid tumours. Following ten years of research and development, it developed EchoPulse®, an innovative ultrasound solution harnessing echotherapy for scar-less ablation of breast and thyroid tumours. Solidly protected by 20 international patent families, EchoPulse® has already received the CE mark and now offers an effective alternative to surgery and mini-invasive techniques.
Theraclion (ticker symbol: ALTHE) was listed through the admission to trading of the 2,854,124 ordinary shares making up the company’s equity, of 155,063 new shares created by the conversion of OCA-13 bonds and 1,000,000 new shares issued under a Global Offering .
The admission and issue price of Theraclion shares was set at €14.50 per share. Market capitalisation was around €54.5 million on the day of listing. Altogether the offering raised nearly €10.9 million.
“We are delighted to accompany Theraclion in its listing on Alternext,” said Eric Forest, Chairman and CEO of EnterNext. “This new stage in the company’s development will mean deploying its innovative technology-based solutions on international markets, and will raise Theraclion’s profile with investors,” he noted.
Theraclion CEO Stefano Vagliani added “Our successful listing gives Theraclion the resources we need to become a leading player in a world market estimated at €6 billion . We are now in a position to step up the development of our distribution network, enhance our R&D efforts and pursue the clinical trials necessary to break into the North American and Chinese markets. Our market listing will also give us greater visibility and facilitate discussions now in progress. I would like to thank all of our employees and partners, in particular Truffle Capital and our new shareholders, for their trust.”